Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Biologically active compounds inhibiting calpain proteases with potential use for the treatment of acute conditions (e.g. ischemia) and degenerative diseases (particularly neurodegenerative diseases) More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 64 pages - $500
Apr 2011 - 64 pages - $2,000
Aug 2011 - 111 pages - $500
Apr 2010 - 115 pages - $3,800
Jan 2011 - 71 pages - $1,000
Apr 2011 - 105 pages - $500
Jan 2012 - 20 pages - $250
Oct 2010 - 112 pages - $7,600
Sep 2011 - 97 pages - $3,500
Oct 2010 - 53 pages - $1,000
Your selection
- Industry sector
- Pharmaceutical del
- Generics del
- Therapeutic target
- Central Nervous System del
- Traumatic brain injury del
Visit also genericlicensing.com
The website which helps the generic industry do business. Visit now
Browse By
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us